Lercanidipine
Lercanidipine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypertension | EFO_0000537 | D006973 | I10 |
| raynaud disease | EFO_1001145 | D011928 | I73.0 |
| stable angina | — | D060050 | I20.8 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C08: Calcium channel blockers
— C08C: Selective calcium channel blockers with mainly vascular effects
— C08CA: Dihydropyridine derivative selective calcium channel blockers with mainly vascular effects
— C08CA13: Lercanidipine
— C09: Agents acting on the renin-angiotensin system
— C09B: Ace inhibitors, combinations
— C09BB: Ace inhibitors and calcium channel blockers
— C09BB02: Enalapril and lercanidipine
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DB08: Valsartan and lercanidipine
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | 5 | 2 | 8 |
| Essential hypertension | D000075222 | I10 | — | 2 | — | 1 | — | 3 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Microvascular angina | D017566 | — | — | — | — | 1 | 1 | ||
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LERCANIDIPINE |
| INN | lercanidipine |
| Description | Lercanidipine is a diarylmethane. |
| Classification | Small molecule |
| Drug class | phenylpyridine vasodilators; tricyclic compounds |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1 |
Identifiers
| PDB | — |
| CAS-ID | 100427-26-7 |
| RxCUI | 135056 |
| ChEMBL ID | CHEMBL250270 |
| ChEBI ID | — |
| PubChem CID | 65866 |
| DrugBank | DB00528 |
| UNII ID | V7XTJ4R0BH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 941 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,215 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more